Clinical trial · Interventional
A Phase 2 Study of HW211026
A Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HW211026 Ointment in Patients With Actinic Keratosis.
NCT07513454CI-TRIAL-00117414not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HW211026 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HW211026 dose 1
- interventionNames
- Drug: HW211026
- type
- EXPERIMENTAL
- label
- HW211026 dose 2
- interventionNames
- Drug: HW211026
Primary outcomes (1)
- measure
- Complete Clearance Rate
- timeFrame
- Day 56
- description
- Percentage of participants achieving 100% clearance of actinic keratosis lesions.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Aged ≥ 18 years, male or female. * 2 to 8 clinically typical target actinic keratosis lesions on the face. * Willing to avoid direct sun or ultraviolet exposure to the treatment area during the trial. * Fully informed about the study, voluntarily sign the informed consent form, and be able to comply with study procedures and follow-up examination requirements. Key Exclusion Criteria: * Target lesions with any of the following conditions: 1) Clinically atypical and/or rapidly changing actinic keratosis lesions, such as hypertrophic lesions, hyperkeratotic lesions, and/or cutaneous horns. 2) Maximum diameter of a single lesion \> 2 cm. 3) Concurrent invasive squamous cell carcinoma, Bowen's disease, basal cell carcinoma or other malignant tumors. 4) Other skin diseases or skin conditions that may interfere with examination or lesion assessment. * Presence of incompletely healed wounds or suspected squamous cell carcinoma, basal cell carcinoma, or other malignant tumors within 5 cm of the actinic keratosis lesions. * Participants with other skin diseases or skin conditions that, in the investigator's judgment, may interfere with the evaluation of safety or efficacy. * Participants who have undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial, as determined by the investigator. * Participants who have participated in any investigational drug clinical trial and received an investigational product within 3 months prior to screening.
References
Publications (0)
Data not yet available
No reference posted for this study.